These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 25860238)
21. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321 [TBL] [Abstract][Full Text] [Related]
22. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience. Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406 [TBL] [Abstract][Full Text] [Related]
23. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma. Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635 [TBL] [Abstract][Full Text] [Related]
24. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205 [TBL] [Abstract][Full Text] [Related]
25. [Prognostic Value of CD14 Wu CX; Qiang M; Hao JQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):816-819. PubMed ID: 31204937 [TBL] [Abstract][Full Text] [Related]
26. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569 [TBL] [Abstract][Full Text] [Related]
27. PD-1 expression on the surface of peripheral blood CD4 Zhang W; Bai JF; Zuo MX; Cao XX; Chen M; Zhang Y; Han X; Zhong DR; Zhou DB Cancer Med; 2016 Nov; 5(11):3077-3084. PubMed ID: 27709793 [TBL] [Abstract][Full Text] [Related]
28. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Rimsza LM; Roberts RA; Miller TP; Unger JM; LeBlanc M; Braziel RM; Weisenberger DD; Chan WC; Muller-Hermelink HK; Jaffe ES; Gascoyne RD; Campo E; Fuchs DA; Spier CM; Fisher RI; Delabie J; Rosenwald A; Staudt LM; Grogan TM Blood; 2004 Jun; 103(11):4251-8. PubMed ID: 14976040 [TBL] [Abstract][Full Text] [Related]
29. [Expression and clinical significance of CD40 in diffuse large B-cell lymphoma]. Wang S; Wang YP; Hao YY; Zheng Y Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):819-23. PubMed ID: 24507100 [TBL] [Abstract][Full Text] [Related]
30. Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy. Gomez-Gelvez JC; Salama ME; Perkins SL; Leavitt M; Inamdar KV Am J Clin Pathol; 2016 Apr; 145(4):514-23. PubMed ID: 27124945 [TBL] [Abstract][Full Text] [Related]
31. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623 [TBL] [Abstract][Full Text] [Related]
32. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665 [TBL] [Abstract][Full Text] [Related]
33. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Cycon KA; Rimsza LM; Murphy SP Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173 [TBL] [Abstract][Full Text] [Related]
34. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143 [TBL] [Abstract][Full Text] [Related]
36. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Alizadeh AA; Gentles AJ; Alencar AJ; Liu CL; Kohrt HE; Houot R; Goldstein MJ; Zhao S; Natkunam Y; Advani RH; Gascoyne RD; Briones J; Tibshirani RJ; Myklebust JH; Plevritis SK; Lossos IS; Levy R Blood; 2011 Aug; 118(5):1350-8. PubMed ID: 21670469 [TBL] [Abstract][Full Text] [Related]
37. High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma. Chang C; Wu SY; Kang YW; Lin KP; Chen TY; Medeiros LJ; Chang KC Am J Clin Pathol; 2015 Dec; 144(6):935-44. PubMed ID: 26573001 [TBL] [Abstract][Full Text] [Related]
38. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575 [TBL] [Abstract][Full Text] [Related]
39. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046 [TBL] [Abstract][Full Text] [Related]
40. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]